The United Kingdom’s regulators allowed a GlaxoSmithKline (GSK) drug called Sotrovimab to treat people having severe Covid-19 symptoms, and the firm claimed that it is effective against the new Omicron variant. The drug was noticed to be safe and effective at decreasing hospitalisation and death of people with severe Covid-19 infections,” the Medicines and Healthcare products Regulatory Agency (MHRA) stated.
Pre-clinical data showed that the drug “holds activity against new Omicron variant. The drug has confirmed ongoing activity against all tested variants of concern and defined by the World Health Organization (WHO),” GSK said in a statement. A single dose of the drug was found to decrease the risk of hospitalisation and death by 79 per cent in high-risk adults with significant Covid-19 infection, according to the MHRA.